SCHEMBL585149

SCHEMBL585149

O=C(O)c1cn(C2CC2)c2c3c(c(F)cc2c1=O)N1CC[C@](O)(CO)C[C@@H]1CO3

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 2/20 0.52
KDM4E B2RXH2 5/20 0.51
ALDH1A1 P00352 4/20 0.51
HPGD P15428 3/20 0.51
HSD17B10 Q99714 3/20 0.51
ALB P02768 1/20 0.51
HRH3 Q9Y5N1 1/20 0.51
POLB P06746 3/20 0.50
TUBB4A P04350 1/20 0.50
TUBB P07437 1/20 0.50
TUBA3C P0DPH7 1/20 0.50
TUBA1B P68363 1/20 0.50
TUBA4A P68366 1/20 0.50
TUBB4B P68371 1/20 0.50
TUBB3 Q13509 1/20 0.50
TUBB2A Q13885 1/20 0.50
TUBB8 Q3ZCM7 1/20 0.50
TUBA3E Q6PEY2 1/20 0.50
TUBA1A Q71U36 1/20 0.50
SLC47A1 Q96FL8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL584219 1.00 AADAT (0.52) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL584526 1.00 AADAT (0.52) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2528014 1.00 AADAT (0.52) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2527668 1.00 AADAT (0.52) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL584176 1.00 AADAT (0.52) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL585343 0.89 ADRB2 (0.46) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL583999 0.89 ADRB2 (0.46) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2526328 0.89 ADRB2 (0.46) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL584564 0.89 ADRB2 (0.46) AADATKDM4EALDH1A1HPGDHSD17B10
SCHEMBL584799 0.89 ADRB2 (0.46) AADATKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069376-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS ACTELION PHARMACEUTICALS, LTD. (CH) 2010-03-18 US claimed
EP-2102217-B1 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS ACTELION PHARMACEUTICALS LTD (CH) 2012-02-15 EP disclosed
US-8039466-B2 5-hydroxymethyl-oxazolidin-2-one antibacterials ACTELION PHARMACEUTICAL LTD. (CH) 2011-10-18 US disclosed
US-20100069376-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS ACTELION PHARMACEUTICALS, LTD. (CH) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069376-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS OGFOD1, ODC1, OXGR1 AADAT 373/4885KDM4E 1273/4885ALDH1A1 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.